We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

To be established over the next few months, the new, hand-picked Board will bring together the most highly experienced scientists with extensive drug discovery backgrounds in the fields of Chronic Pain and CNS research, extending Cellectricon’s expertise in these areas. 

“Cellectricon is assembling a first-class team of scientists and engineers - all focused on the challenging task of developing enhanced assay technologies for early stage Pain and CNS drug discovery” said Dr Johnson. “I am pleased to join its Scientific Advisory Board and look forward to helping the company as it pursues this mission.”

Edwin Johnson has over 20 years’ experience in CNS discovery and development, especially in the areas of neuroscience. With over 50 peer-reviewed publications and 10 patents, he has been extensively involved in numerous drug discovery programmes. In addition, he has also headed up teams working on drugs for the treatment of cognitive disorders, Parkinson’s disease and depression, taking them through clinical development. Since 2012, Edwin has headed the Stockholm Brain Institute and is the CNS lead at Karolinska Institutet Innovations.

“In the past 12 months we have gained significant traction with our Discovery Services offering based on our proprietary Cellaxess® Elektra phenotypic assay platform and expert scientific staff”, said Cellectricon’s CEO, David Burns. “In order to further add value, we are expanding our Discovery Services offering to include a range of complementary cell-based assays that encompass profiling further along the drug discovery process. We are very pleased to welcome Dr Johnson to our newly-formed Scientific Advisory Board, as he will provide valuable domain knowledge that will aid the development of our proprietary Discovery Services for our clients.”